Skip to main content

Red Sox-Nationals Curtis Mead trade spoils the market for Mariners and everyone else

Dang it, Red Sox.
Mandatory Credit: Rafael Suanes-Imagn Images
Mandatory Credit: Rafael Suanes-Imagn Images | IMAGN IMAGES via Reuters Connect

What is one Curtis Mead worth? The Washington Nationals apparently thought he was worth one Connelly Early, and the Boston Red Sox apparently agreed. That's how the big trade between the two sides came together Saturday, and the fallout isn't helpful for the Seattle Mariners or anyone else shopping in a certain corner of the trade market.

With the MLB trade deadline looming on August 3, Mead-for-Early was the first big deal of the summer trading season. Even if it succeeds in doing nothing else, it has already succeeded in setting the market for right-handed hitters. And not in a buyer-friendly way, as ESPN's Buster Olney observed:

Baseball Trade Values backs up Olney's assertion that Early-for-Mead was an "excessive" overpay for Boston. They had the surplus value gap between Early and Mead in the range of $20 million in favor of Early, even though he's currently on the IL with elbow inflammation. In no universe should this have been a fair trade.

While both Early and Mead are former top-100 prospects, that was true of Early last year, whereas Mead was last a top prospect in 2024. Further, the 24-year-old Early has accrued more rWAR in 21 career starts than Mead has in 239 career games. Early has also never been designated for assignment. Mead was as recently as this March by the Chicago White Sox.

The Curtis Mead trade paints a grim picture of right-handed hitting in 2026

Just for starters, we'll reiterate that it should have been the Mariners who traded for Mead. He fit their needs like a proverbial glove, and they lined up just as well as a trading partner for the Nationals as Boston did.

That said, a Mead-for-Emerson Hancock also would have been considered an overpay by Baseball Trade Values. And that's even though their profiles line up better than those of Mead and Early. Hancock is likewise a couple years removed from being a top prospect, and likewise finally breaking out in 2026. Moreover, he and Mead are both scheduled to hit free agency after 2030.

So, what's the deal? Is Mead undervalued by Baseball Trade Values? Is Early overvalued? Did the Red Sox just decide it was worth it to throw caution to the wind and overpay? Or did they make a bet that Mead was about to be overvalued by the invisible hand of the trade market?

All of these things can be true, and yet it does seem especially likely that the Red Sox had the right idea on Mead's valuation. He's a righty hitter with a 133 OPS+. There are only 38 qualified righty hitters with at least a 100 OPS+ this year, on track for the fewest since 1972.

Mariners could pay the price for the price the Red Sox put on Curtis Mead

If the market for right-handed hitting was already thin before the Mead trade, it's even thinner now that he's off the board. Worse, injuries may have nixed Matt Shaw and Spencer Steer as targets. It leaves one to wonder what fresh hell awaits Jerry Dipoto in negotiations over what options are left.

As an example, consider San Francisco Giants utility man Casey Schmitt. He's more established than Mead, but he's also older and less controllable. He also hasn't been as productive in 2026, posting "only" a 118 OPS+ and 1.4 rWAR. In theory, a Hancock-for-Schmitt swap would be even more of an overpay than a Hancock-for-Mead swap would have been.

But in reality, that may not be the case anymore. If so, maybe that means the Mariners couldn't also command a reliever from the Giants in a Hancock-for-Schmitt trade. Worse, maybe it means they'd actually have to realize that wild George Kirby idea in order to get Schmitt to Seattle.

Given the reality of right-handed hitting in 2026, perhaps there was never any avoiding such binds for the Mariners. But thanks to the Red Sox, getting a good deal on a righty bat is now a matter of hope as much as anything else.

Add us as a preferred source on Google

Loading recommendations... Please wait while we load personalized content recommendations